Emergent BioSolutions

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell EBS and other ETFs, options, and stocks.

About EBS

Emergent BioSolutions Inc. engages in the development, manufacture, and commercialization of medical countermeasures. It operates through the following segments: Commercial Product Sales, MCM Product Sales, and Services. 

CEO
Joseph C. Papa
CEOJoseph C. Papa
Employees
900
Employees900
Headquarters
Gaithersburg, Maryland
HeadquartersGaithersburg, Maryland
Founded
1998
Founded1998
Employees
900
Employees900

EBS Key Statistics

Market cap
260.72M
Market cap260.72M
Price-Earnings ratio
-1.43
Price-Earnings ratio-1.43
Dividend yield
Dividend yield
Average volume
1.63M
Average volume1.63M
High today
$5.11
High today$5.11
Low today
$4.75
Low today$4.75
Open price
$4.81
Open price$4.81
Volume
1.42M
Volume1.42M
52 Week high
$14.06
52 Week high$14.06
52 Week low
$4.36
52 Week low$4.36

Stock Snapshot

With a market cap of 260.72M, Emergent BioSolutions(EBS) trades at $5.02. The stock has a price-to-earnings ratio of -1.43.

On 2026-08-23, Emergent BioSolutions(EBS) stock traded between a low of $4.75 and a high of $5.11. Shares are currently priced at $5.02, which is +5.6% above the low and -1.7% below the high.

The Emergent BioSolutions(EBS)'s current trading volume is 1.42M, compared to an average daily volume of 1.63M.

In the last year, Emergent BioSolutions(EBS) shares hit a 52-week high of $14.06 and a 52-week low of $4.36.

In the last year, Emergent BioSolutions(EBS) shares hit a 52-week high of $14.06 and a 52-week low of $4.36.

EBS News

TipRanks 2d
Emergent BioSolutions reinstated with an Underweight at JPMorgan

JPMorgan reinstated coverage of Emergent BioSolutions (EBS) with an Underweight rating and no price target The company is in a transition phase, with the recent...

Investing.com 5d
S&P downgrades Emergent BioSolutions outlook on competition - Investing.com

...

S&P downgrades Emergent BioSolutions outlook on competition - Investing.com
TipRanks 6d
Emergent BioSolutions Balances Q2 Beat With Tough Outlook

Emergent Biosolutions ((EBS)) has held its Q2 earnings call. Read on for the main highlights of the call. Summer Sale - Claim 70% Off TipRanks Unlock powerful i...

People also own

Based on the portfolios of people who own EBS. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.